[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unknown-primary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unknown-primary-cancer":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100278638","ontario-wide-cancer-targeted-nucleic-acid-evaluation-100278638",false,"NCT02906943","Ontario-wide Cancer TArgeted Nucleic Acid Evaluation","OCTANE","Inclusion Criteria:\n\n1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.\n2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.\n3. Patient must be ≥ 18 years old.\n4. Patient's ECOG performance status equal to 0 or 1.\n5. All patients must have a life expectancy of \\> 6 months.\n6. All patients must have adequate organ functions.\n7. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1\\. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent\u002Fmetastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.","ALL","18 Years",{"count":19,"type":20},10000,"ESTIMATED","OBSERVATIONAL","Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.\n\nBiomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.\n\nThe study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient.\n\nAnother goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research.\n\nThe study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.",[24,25,26,27,28,29,30,31,32,33,34],"Breast Cancer","Lung Cancer","Colorectal Cancer","Melanoma","Gynecological Cancer","Genitourinary Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Cancer",[36,37,38,39,40],"Molecular Profiling","Advanced Cancer","Advanced Solid Tumors","Phase I Clinical Trial Candidates","Next Generation Sequencing","RECRUITING","2026-06-03",{"date":44,"type":45},"2026-06-05","ACTUAL",{"date":47,"type":4},"2016-08",{"date":49,"type":20},"2027-08",{"name":51,"class":52},"University Health Network, Toronto","OTHER",7,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100483587","phase-2-a-phase-2a-single-dose-open-label-study-to-evaluate-diagnostic-performance-and-safety-of-pegsitacianine-an-intraoperative-fluorescence-imaging-agent-for-the-detection-of-cancer-in-patients-with-unknown-primary-head-and-neck-cancer-illuminate-study-100483587","NCT05576974","A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)","Inclusion Criteria:\n\n1. Adults ≥18 years of age\n2. Biopsy-confirmed diagnosis, for primary or recurrent disease (or high clinical suspicion in the opinion of the Investigator)\n\n   1. Part 1: Stage 1 to 4 HNSCC\n   2. Part 2: UPC squamous cell carcinoma of the head and neck with metastatic disease to at least a single cervical node, AND no biopsy proven evidence of the primary cancer's location.\n3. Acceptable hematologic status (as standard surgery protocol requires, as determined by the Investigator), kidney function and liver function. Elevations of creatinine, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin \\>1.5× the upper limit of normal \\[ULN\\] must be determined to be not clinically significant by the Investigator and approved by the Medical Monitor.\n4. Documented negative serum pregnancy test for women of childbearing potential (i.e., premenopausal women with intact reproductive organs and women \\\u003C2 years after menopause)\n5. Male patients and female patients of child-bearing potential (i.e., premenopausal women with intact reproductive organs and women \\\u003C2 years after menopause) must agree to and comply with using medically acceptable contraception including surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation), intrauterine device, oral contraceptive, contraceptive patch, long acting injectable contraceptive, partner's vasectomy, double-barrier method (condom or diaphragm plus spermicide or condom plus diaphragm), or abstinence during the trial and for 6 months thereafter\n6. Agree to abstain from alcohol consumption from 72 hours before Pegsitacianine administration through completion of Study Day 10 (±48 hours) visit in Part 1 and Part 2.\n7. Adequate potential for follow up\n\nExclusion Criteria:\n\n1. Tumors at sites of which the surgeon would assess that in vivo intraoperative imaging would not be feasible.\n2. Life expectancy \\\u003C12 weeks\n3. Karnofsky Performance Status \\\u003C70%\n4. Hepatic impairment (Child-Pugh score \\>5) or significant liver disease including active hepatitis or cirrhosis\n5. Lab values or any sign, symptom, or medical condition that in the opinion of the PI would prevent surgical resection\n6. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.\n7. Pregnant or lactating women\n8. Receiving or planned to receive, during the duration of the study, concomitant medication with a high chance of hepatotoxicity, as judged by the PI based on standard protocols within the study center\n9. Alcohol consumption within 72 hours before Pegsitacianine administration\n10. Received an investigational agent within the shorter of 5 half-lives or 30 days before Pegsitacianine dosing\n11. Inability to adhere to the schedule of assessments or any circumstance that would interfere with the validity of assessments performed in the study\n12. The PI considers that the patient should not participate in the study","99 Years",{"count":62,"type":20},120,"INTERVENTIONAL",[65],"PHASE2","This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.",[32,34,68],"Head and Neck Squamous Cell Carcinoma","2026-04-09",{"date":71,"type":45},"2026-04-14",{"date":73,"type":45},"2024-04-17",{"date":75,"type":20},"2027-12-31",{"name":77,"class":52},"University of Texas Southwestern Medical Center",1]